Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.55 |
| ▸ | CES1 | P23141 | 4/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2575677 | 1.00 | CES2 (0.55) | CES2CES1BCHEHPGDALB | |
| SCHEMBL18554814 | 0.85 | ALDH1A1 (0.53) | CES2CES1HPGDALBALDH1A1 | |
| SCHEMBL149580 | 0.85 | ALDH1A1 (0.53) | CES2CES1HPGDALBALDH1A1 | |
| SCHEMBL10120007 | 0.79 | CES2 (0.54) | CES2CES1BCHEHPGDALB | |
| SCHEMBL2575629 | 0.78 | CES2 (0.50) | CES2CES1BCHEHPGDALB | |
| SCHEMBL2575630 | 0.78 | CES2 (0.50) | CES2CES1BCHEHPGDALB | |
| SCHEMBL29772247 | 0.77 | CES2 (0.68) | CES2CES1BCHEHPGDALB | |
| SCHEMBL717464 | 0.77 | CES2 (0.68) | CES2CES1BCHEHPGDALB | |
| SCHEMBL1975197 | 0.75 | CES2 (0.65) | CES2CES1BCHEHPGDALB | |
| SCHEMBL29119468 | 0.75 | ALDH1A1 (0.61) | HPGDALDH1A1ALOX15NR4A1NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102187-B1 | SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES AS INHIBITORS OF RHO-KINASE | SANOFI SA (FR) | 2015-04-01 | — | — | EP | disclosed |
| US-8461144-B2 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2013-06-11 | — | — | US | disclosed |
| EP-2385047-B1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI SA (FR) | 2013-05-29 | — | — | EP | disclosed |
| EP-1910333-B1 | PIPERIDINYL-SUBSTITUTED ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI SA (FR) | 2013-05-22 | — | — | EP | disclosed |
| US-20120316152-A1 | SUBSTITUTED ISOQUINOLINEAND ISOQUINOLINONE DERIVATIVES | SANOFI (FR) | 2012-12-13 | — | — | US | disclosed |
| US-8278294-B2 | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of Rho-kinase | SANOFI (FR) | 2012-10-02 | — | — | US | disclosed |
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| EP-2385047-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI (FR) | 2011-11-09 | — | — | EP | disclosed |
| US-20100063025-A1 | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of RHO-Kinase | SANOFI-AVENTIS (FR) | 2010-03-11 | — | — | US | disclosed |
| EP-2102187-A1 | SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES AS INHIBITORS OF RHO-KINASE | Sanofi-Aventis (FR) | 2009-09-23 | — | — | EP | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
| WO-2008077550-A1 | SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES AS INHIBITORS OF RHO-KINASE | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063025-A1 | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of RHO-Kinase | ROCK1, MYLK, ROCK2 | CES2 4134/4885CES1 3048/4885BCHE 2562/4885 |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | MYLK2, MYLK, RHOT2 | CES2 3840/4885CES1 2743/4885BCHE 3883/4885 |
| US-20120316152-A1 | SUBSTITUTED ISOQUINOLINEAND ISOQUINOLINONE DERIVATIVES | MYLK2, RHOT2, MYLK | CES2 3083/4885CES1 2772/4885BCHE 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.